{
    "clinical_study": {
        "@rank": "35235", 
        "arm_group": [
            {
                "arm_group_label": "Treatment-Naive Patients", 
                "arm_group_type": "Experimental", 
                "description": "VT-464: given orally twice daily in 28 day cycles"
            }, 
            {
                "arm_group_label": "Previous abiraterone but chemo-naive", 
                "arm_group_type": "Experimental", 
                "description": "VT-464: given orally twice daily in 28 day cycles"
            }, 
            {
                "arm_group_label": "Previous enzalutamide but chemo-naive", 
                "arm_group_type": "Experimental", 
                "description": "VT-464: given orally twice daily in 28 day cycles"
            }, 
            {
                "arm_group_label": "Previous abiraterone, enzalutamide and/or chemo", 
                "arm_group_type": "Experimental", 
                "description": "VT-464: given orally twice daily in 28 day cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics\n      and activity of VT-464, a lyase-selective inhibitor of CYP17,  in patients with\n      castration-resistant prostate cancer (CRPC)."
        }, 
        "brief_title": "A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Castration-resistant Prostate Cancer", 
            "CRPC"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1/2 study of VT-464 in treatment-na\u00efve patients CRPC and CRPC patients who\n      have failed prior therapy with abiraterone, enzalutamide, and/or chemotherapy.  The study\n      consists of 2 phases: a dose-escalation phase (Phase 1) and a cohort-expansion phase (Phase\n      2).  Phase 1 will be an open-label, multicenter, sequential-dose cohort design in\n      treatment-naive patients and Phase 2 will be an open-label, multicenter, parallel-group\n      design and treatment-naive and treatment-failure patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Patients must have documented histological or cytological evidence of adenocarcinoma\n             of the prostate.\n\n          -  Patients must have a minimum serum PSA level of >2 ng/ml that is rising based on the\n             Prostate Cancer Working Group 2 criteria.\n\n          -  Patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l]).\n\n          -  Patients must have undergone orchiectomy, or have been on LHRH agonists or\n             antagonists, for at least 3 months prior to study entry.  Patients on LHRH\n             agonists/antagonists must remain on these agents for the duration of the study.\n\n          -  Patients must have an ECOG Performance Score of 0 or 1.\n\n        Key Exclusion Criteria:\n\n          -  Patients who have received prior cytotoxic chemotherapy for prostate cancer unless\n             enrolled in a previous chemotherapy cohort.\n\n          -  Patients who have received second-line antihormonal therapy, including ketoconazole,\n             aminoglutethimide, or high-dose estrogen within 30 days of study entry.\n\n          -  Patients who have completed sipuleucel-T (Provenge \u00ae) treatment within 30 days of\n             study entry.\n\n          -  Patients who have received abiraterone (Zytiga\u00ae), TAK-700 (Orteronel\u00ae), TOK-001\n             (Galeterone\u00ae), or MDV3100, or any other investigational product directed towards the\n             androgen receptor or androgen biosynthesis. Previous abiraterone and enzalutamide are\n             allowed in certain treatment-failure cohorts\n\n          -  Patients who have received antiandrogens such as flutamide (EULEXIN\u00ae), bicalutamide\n             (CASODEX\u00ae), or nilutamide (NILANDRON\u00ae) for > 3 months must be off treatment for 6\n             weeks and demonstrate  a continued rise in PSA after withdrawal.  Patients on\n             antiandrogens for < 3 months must be off medication for 2 weeks. Patients on 5 alpha\n             reductase inhibitors such as finasteride (PROSCAR\u00ae, PROPECIA\u00ae), or dutasteride\n             (AVODART\u00ae) must stop medication at least 3 months from study entry.\n\n          -  Patients who require pharmacological or replacement doses of systemic corticosteroids\n             or who have received systemic corticosteroids within 30 days of study entry; use of\n             topical, inhaled or ophthalmic steroids is permitted.\n\n          -  Patients who have received palliative radiotherapy within 4 weeks of study entry.\n\n          -  Patients with a history within the last 3 years of another invasive malignancy."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "141", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012920", 
            "org_study_id": "VMT-VT-464-CL-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment-Naive Patients", 
                "Previous abiraterone but chemo-naive", 
                "Previous enzalutamide but chemo-naive", 
                "Previous abiraterone, enzalutamide and/or chemo"
            ], 
            "intervention_name": "VT-464: given orally twice daily in 28 day cycles", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "castration-resistant prostate cancer", 
            "CYP17", 
            "P450c17a", 
            "lyase"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "wphilips@gucancer.com", 
                    "last_name": "Wendie Philips, RN", 
                    "phone": "402-991-8468"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68130"
                    }, 
                    "name": "Urology Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Luke Nordquist, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Debbie.Dios@usoncology.com", 
                    "last_name": "Debbie Dios, RN", 
                    "phone": "702-952-3400"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "86169"
                    }, 
                    "name": "Comprehensive Cancer Centers of Nevada"
                }, 
                "investigator": [
                    {
                        "last_name": "Nicholas J Vogelzang, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Oscar Goodman, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "donna.mcneil@duke.edu", 
                    "last_name": "Lynn McNeil, RN", 
                    "phone": "919-684-1390"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Daniel George, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patricia.robinson@usoncology.com", 
                    "last_name": "Patricia Robinson, RN", 
                    "phone": "919-510-5637"
                }, 
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27607"
                    }, 
                    "name": "Cancer Centers of North Carolina"
                }, 
                "investigator": {
                    "last_name": "William Berry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jgriffith@atlanticurologyclinics.com", 
                    "last_name": "Jennifer Griffith", 
                    "phone": "843-449-1010", 
                    "phone_ext": "316"
                }, 
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29572"
                    }, 
                    "name": "Carolina Urologic Research Center"
                }, 
                "investigator": {
                    "last_name": "Neal Shore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mstorms@mdanderson.org", 
                    "last_name": "Mary Beth Storms, RN", 
                    "phone": "713-563-7244"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "John C Araujo, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kssimmons@medicine.wisc.edu", 
                    "last_name": "Kelly Simmons, B.A.", 
                    "phone": "608-263-7107"
                }, 
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Carbone Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Glenn Liu, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rgyftaki@gmail.com", 
                    "last_name": "Revekka Gyftaki", 
                    "phone": "+30 6937064958"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11528"
                    }, 
                    "name": "Alexandria Hospital, Department of Oncology"
                }, 
                "investigator": {
                    "last_name": "Eleni Efstathiou, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Brian.Meehan@kssg.ch", 
                    "last_name": "Brian Meehan, RN"
                }, 
                "facility": {
                    "address": {
                        "city": "St Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Kantonsspital St Gallen, Onkologie/ Hamatologie"
                }, 
                "investigator": [
                    {
                        "last_name": "Silke Gillessen, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Aurelius Omlin, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alan.smith@icr.ac.uk", 
                    "last_name": "Alan Smith, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey"
                    }, 
                    "name": "The Royal Marsden Hospital - Institute of Cancer Research"
                }, 
                "investigator": [
                    {
                        "last_name": "Johann De Bono, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alan Smith, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Greece", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer", 
        "other_outcome": [
            {
                "measure": "The change in PSA from baseline using waterfall plots in response to VT-464", 
                "safety_issue": "No", 
                "time_frame": "At least monthly over the first 8 28-day dosing cycles"
            }, 
            {
                "measure": "Objective tumor response to VT-464 at the end of even-numbered cycles using RECIST 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "At least every other month over the first 8 28-day dosing cycles"
            }, 
            {
                "measure": "The absolute and percent change from baseline in adrenal, pituitary, and testicular hormone concentrations in response to VT-464", 
                "safety_issue": "No", 
                "time_frame": "At least monthly over the first 8 28-day dosing cycles"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The safety and tolerability of VT-464 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.", 
            "safety_issue": "No", 
            "time_frame": "The first 28-day continuous dosing cycle at target dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The pharmacokinetics of VT-464 using measures that include Cmax, Tmax and AUC", 
            "safety_issue": "No", 
            "time_frame": "The first 28-day continuous dosing cycle at target dose."
        }, 
        "source": "Viamet Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Viamet Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}